Lymph Node Ratio and Kras Mutation in R Colon Cancer

Mansoura University

Status and phase: Completed; Phase 3

Conditions: Colon Cancer Stage III

Treatments: Drug: Panitumumab; Device: k ras

Study type: Interventional

Funder types: Other

Identifiers

NCT04342676

IRB 20202

Details and patient eligibility

About

clinical impact of LN ratio with Kras expression in colon cancer

Full description

LNR and K ras were evaluated with correlated with different clinicopathological parameters of the patients, PFS and OS.

Enrollment: 433 patients

Sex: All

Ages: 16 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Stage III colon cancer

Exclusion criteria

• Stage I, II, IV

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

433 participants in 1 patient group

patients

Experimental group

Description:

LNR measured by (number of metastatic lymph nodes/total number of lymph nodes excised). and K ras (polymerase chain reaction (PCR) and pyrosequencing targeted for KRAS codons 12-13 was performed )

Treatment:

Device: k ras

Drug: Panitumumab